Jeffrey N. Fredman
102 IP cases indexed. Covers patent matters.
Cases Presided Over
102 cases indexed | Page 4 of 4
Imperative Care, Inc. v.INARI MEDICAL, INC.
Imperative Care, Inc. successfully challenged nine claims of INARI MEDICAL's hemostasis valve patent (11697011) at the PTAB. The Board found sufficient evidence for Petitioner’s anticipation challenge against Claim 1 after adopting a broad interpretation of the term 'filament.'
Imperative Care, Inc. v.INARI MEDICAL, INC.
The Board found that the claims were unpatentable under obviousness (Grounds 3 and 4), specifically over a combination of Schaffer's valve with Hartley's string or Eller's wire. The decision hinged on finding that a POSA would have had reason to make this substitution, leading to predictable results in hemostatic device design.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef and Institute for Environmental Health settled four inter partes reviews covering patents 7,534,584; 8,822,143; 9,637,771; and 9,845,486. The Board terminated the proceedings based on a written settlement agreement and granted confidentiality for the agreement.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef Packing Company successfully challenged claims 1-30 of the '486 patent in a PTAB Institution Decision, establishing a reasonable likelihood that the methods for pathogen detection are unpatentable. The petitioner relied on prior art references including Rayman and Nagar to demonstrate anticipation and obviousness across multiple grounds.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef and Institute for Environmental Health settled four inter partes review proceedings, resulting in the termination of all petitions without a merits decision. The Board granted the joint motion to terminate and kept the settlement agreement confidential.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef Packing Company successfully petitioned to institute IPR against the '771 patent, establishing a reasonable likelihood of success over at least one claim. The Board adopted Petitioner's definition for 'validation,' clarifying that it merely requires a sample test negative, rejecting the Patent Owner's broader interpretation regarding commercial release.
PreOmics GmbH et al. v.The Brigham and Women’s Hospital, Inc.
PreOmics GmbH et al. successfully petitioned for institution in the IPR against The Brigham and Women’s Hospital, Inc., challenging claims related to sensor arrays for protein corona analysis. The Board found a reasonable likelihood of unpatentability based on grounds of anticipation (102) and obviousness (103).
PreOmics GmbH et al. v.The Brigham and Women’s Hospital, Inc.
The Board found that six claims (1, 4, 6, 17, 22, and 25) of the patent were unpatentable based on anticipation by prior art Cai. The decision hinged on a broad interpretation of key terms like 'biological sample' and 'subset of particles,' which favored the Petitioner's arguments regarding the scope of the claims.
Front Line Medical Technologies Inc. v.Prytime Medical Devices, Inc.
The PTAB institution decision found that the petitioner successfully demonstrated a likelihood of prevailing on its obviousness challenges against all ten claims. The Board adopted broad claim constructions for 'proximal hub' and 'flow valve,' finding they could be separate or sub-elements, which supported the grounds of obviousness over various prior art combinations.
Front Line Medical Technologies Inc. v.Prytime Medical Devices, Inc.
Petitioner successfully demonstrated that all ten challenged claims related to vascular occlusion catheters are unpatentable by a preponderance of the evidence. The Board relied heavily on various combinations of prior art references, primarily under 35 U.S.C. § 103 (obviousness).
Vectair Systems Inc. v.Fresh Products, Inc.
Vectair Systems Inc.'s IPR challenge against Fresh Products, Inc.'s patent was denied by the PTAB. The Board found that the Petitioner failed to establish a reasonable likelihood of prevailing on grounds of anticipation (102) or obviousness (103).
Sarepta Therapeutics, Inc et al. v.The Trustees of the University of Pennsylvania et al.
The Board issued a Final Written Decision upholding the validity of claim 8 in this gene therapy IPR. The decision found that Petitioner failed to demonstrate sufficient motivation or reasonable expectation of success to combine prior art references under 35 U.S.C. § 103(a).
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.